Clinical trials: Oligodendroglioma of Brain
Glioblastoma Multiforme, Anaplastic Astrocytoma
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age.
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Fibrillary Astrocytomas, Oligodendroglioma
- Trial name
- NCT05956821
- Testing
- SIACI of cetuximab and bevacizumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Miami
Quality of Life, Cognitive Impairment
Long Term Implications of Rare Brain Tumours'
Patients diagnosed with oligodendroglioma with a specific molecular profile represent rare tumour groups (about 10% of adult gliomas) with relatively favourable prognosis (median survival between 8 and 12 years).
- Conditions
- Quality of Life, Cognitive Impairment, WHO Grade II Oligodendroglial Tumor, WHO Grade III Oligodendroglial Tumor
- Trial name
- NCT04708548
- Testing
- Health-related Quality of Life, Psychological Distress, Fatigue
- Where
- 2 sites in Netherlands, United Kingdom
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Galina Velikova
Malignant Gliomas, Astrocytomas
Clinical Development of MR Spectroscopy and Imaging in Brain Cancers
The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in isocitrate dehydrogenase (IDH) mutated gliomas and…
- Conditions
- Malignant Gliomas, Astrocytomas, Oligodendrogliomas
- Trial name
- NCT02731521
- Testing
- 3 Tesla Scanning, 7 Tesla Scanning
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center